The recent introduction of treatment options with proven benefits on cardiorenal outcomes in HF regardless of the presence of diabetes [(i.e. sacubitril/valsartan, sodium-glucose cotransporter-2 inhibitors (SGLT2i), and non-steroidal mineralocorticoid receptor antagonists (MRA)] calls for its better characterization [9–11]. The gene discussed is SLC5A2; the disease is diabetes mellitus.